ERBB2 and breast carcinoma: In contrast to our discovery, in a pooled analysis of four prospective clinical trials including 2,310 early breast cancer patients, Denkert et al. demonstrated that HER2‐low patients had significantly longer survival than HER2‐0 patients.10